H. Roché

发表

A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC).

H. Wildiers, J. Jassem, L. Dirix, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Potential prognostic value in human breast cancer of cytosolic Nme1 protein detection using an original hen specific antibody.

C. Toulas, G. Favre, J. Mihura, 1996, British Journal of Cancer.

LANDSCAPE: An FNCLCC phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (+) metastatic breast cancer (MBC) before whole-brain radiotherapy (WBR).

M. Campone, G. Romieu, J. Pierga, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel

J. Machiels, M. Berlière, F. Dalenc, 2008, BMC Cancer.

Incidence of reversible amenorrhea in women with early-stage breast cancer undergoing adjuvant anthracyclin-based chemotherapy with or without docetaxel.

J. Machiels, M. Berlière, F. Dalenc, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Regulation of senescence escape by TSP1 and CD47 following chemotherapy treatment

J. Lemonnier, M. Campone, O. Coqueret, 2019, Cell Death & Disease.

Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen

Catherine Charbonnel, Wilfried Gouraud, Pascal Jézéquel, 2008, Breast Cancer Research and Treatment.

Anastrozole and goserelin combination as first treatment for premenopausal receptor positive advanced or metastatic breast cancer: A phase II trial.

M. Campone, C. Veyret, H. Roché, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

PP-5-6 Castration and Tamoxifen Versus Chemotherapy (FAC) for Premenopausal, Node and Receptors Positive Breast Cancer Patients: A Randomized Trial with a 7 Years Median Follow Up

A. Naja, J. Mihura, J. Dubois, 1996 .

272P Outcomes of patients (pts) who had received prior platinum (PP) therapy in the phase III EMBRACA trial of talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC)

S. Hurvitz, T. Usari, K. Lee, 2021, Annals of Oncology.

Regulation of senescence escape by TSP1 and CD47 following chemotherapy treatment

J. Lemonnier, M. Campone, O. Coqueret, 2019, Cell Death & Disease.

Dose-intensified chemotherapy and additional Docetaxel may improve inflammatory breast cancer patients outcome over two decades: Results from Institut Curie protocols 1977–1987 and two consecutive French multicenter trials Pegase 02 (1995–96) and Pegase 05 (1997–99)

B. Asselain, J. Pierga, P. Viens, 2004 .

Dose-intensified chemotherapy and additional Docetaxel may improve inflammatory breast cancer patients outcome over two decades: Results from Institut Curie protocols 1977-1987 and two consecutive French multicenter trials Pegase 02 (1995-96) and Pegase 05 (1997-99).

B. Asselain, J. Pierga, P. Viens, 2004, Journal of Clinical Oncology.

High-Dose Chemotherapy for Breast Cancer in Europe

M. Marangolo, A. Gratwohl, P. Viens, 1999 .

HIGH-DOSE CHEMOTHERAPY FOR BREAST

A. Gratwohl, P. Viens, H. Roché, 1999 .